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Abstract
Molecular chaperones of the heat shock protein 70
(Hsp70) family play a crucial role in the presentation of
exogenous antigenic peptides by antigen-presenting
cells (APCs). In a combined biochemical and immuno-
logical approach, we characterize the biochemical inter-
action of tumor-associated peptides with human Hsp70
and show that the strength of this interaction determines
the efficacy of immunological cross-presentation of the
antigenic sequences by APCs. A fluorescein-labeled
cytosolic mammalian Hsc70 binding peptide is shown to
interact with human Hsp70 molecules with high affinity
(Kds0.58 mM at 258C). Competition experiments dem-
onstrate weaker binding by Hsp70 of antigenic peptides
derived from the tumor-associated proteins tyrosinase
(Kds32 mM) and melanoma antigen recognized by T cells
(MART-1) (Kds2.4 mM). Adding a peptide sequence
(pep70) with high Hsp70 binding affinity (Kds0.04 mM) to
the tumor-associated peptides enables them to strongly
interact with Hsp70. Presentation of tumor-associated
peptides by B cells resulting in T cell activation in vitro is
enhanced by Hsp70 when the tumor-associated peptides
contain the Hsp70 binding sequence. This observation
has relevance for vaccine design, as augmented transfer
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of tumor-associated antigens to APCs is closely linked
to the vaccine’s efficacy of T cell stimulation.
Keywords: antigen presentation; antigenic peptide;
anti-tumor T cell response; heat shock protein 70;
molecular chaperone; peptide binding.
Introduction
The highly conserved 70 kDa heat shock proteins
(Hsp70) are molecular chaperones involved in the folding
of newly synthesized polypeptides, refolding of misfolded
proteins, membrane translocation and control of regula-
tory proteins (Hartl and Hayer-Hartl, 2002; Mayer and
Bukau, 2005). They achieve their functions through inter-
action with short hydrophobic stretches within protein
substrates, and are capable of binding short peptides
in vitro (Flynn et al., 1991; Landry et al., 1992; Blond-
Elguindi et al., 1993; Gragerov and Gottesman, 1994;
Ru¨diger et al., 1997; Knarr et al., 1999). Both stress-
inducible Hsp70 and constitutively expressed 70 kDa
heat shock cognate (Hsc70) isoforms occur in the cyto-
plasm of mammalian cells.
Hsp70 molecules possess a highly conserved amino
(N)-terminal ATPase domain which regulates the opening
and closing of the carboxy (C)-terminal peptide binding
domain. It appears that the adenosine triphosphate
(ATP)-bound form of Hsp70 has low affinity and fast
exchange rates for substrate proteins and peptides, and
undergoes slow hydrolysis to the adenosine diphosphate
(ADP)-bound form, which has high affinity and low
exchange rates for substrates (Mayer and Bukau, 2005).
The substrate-binding domain consists of an 8-stranded
antiparallel b-sandwich with a hydrophobic cavity,
covered by an a-helical ‘lid’ domain (Zhu et al., 1996;
Stevens et al., 2003).
The crystal and solution structures of complexes of the
substrate-binding domain with a bound peptide suggest
that backbone hydrogen bonding holds an extended
pentapeptide in the cavity of bacterial Hsp70 (DnaK), with
a central leucine residue accommodated in a deep
hydrophobic pocket (Zhu et al., 1996; Stevens et al.,
2003). Presumably ATP binding triggers opening of the
binding cavity, facilitating substrate release.
Recent work suggests localization of Hsp70 to the
plasma membrane of cancer cells and a role for extra-
cellular Hsp70 in anti-tumor immunity (Milani et al., 2002;
Multhoff, 2002). Molecular chaperones isolated from
tumor cells can elicit anti-tumor immunity in vivo and
in vitro (Udono and Srivastava, 1993, 1994; Suto and
Srivastava, 1995). They were found to be associated with
antigenic peptides (Ishii et al., 1999), which they appear
to transport to antigen-presenting cells (APCs) for cross-
presentation (Castellino et al., 2000; Noessner et al.,
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Table 1 Equilibrium binding parameters of peptide interaction with human Hsp70.
Additive Peptide Sequencea Kd (mM)
258C 378C
FAF-1 f-FYQLALT 0.58"0.10 5.0"0.9
1 mM ADP FAF-1 f-FYQLALT 1.7"0.2
AF-1 FYQLALT 0.87"0.06 2.3"0.1
pep70 HWDFAWPW 0.039"0.006
Tyrosinase YMNGTMSQV 31.6"4.5
MART-L LAGIGILTV 1.6"0.2
MART-1 AAGIGILTV 2.4"0.8
pep70-tyrosinase b-GSGHWDFAWPWGSGYMNGTMSQV 0.056"0.007
pep70-MART-L b-GSGHWDFAWPWGSGLAGIGILTV 0.093"0.022
af, fluorescein; b, biotin.
2002; Ueda et al., 2004; Zheng and Li, 2004). The pres-
entation of exogenous antigens by major histocompati-
bility complex (MHC) class I molecules on the APC
surface leads to specific anti-tumor immunity (Calder-
wood et al., 2005). Antigenic peptides vary in their hydro-
phobic content and their binding affinity for molecular
chaperones. Enhanced delivery of exogenous antigens
by Hsp70 to APCs leads to stronger T cell responses
(Bendz et al., 2007). This function can be utilized in the
generation of protein-based vaccines that are intended
to stimulate antigen-specific CD8 T cell responses.
Fusion of the antigenic peptides with a motif known to
bind BiP (Flynn et al., 1991), an Hsp70 isoform in the
endoplasmic reticulum (also named grp78), has been
used to enhance their interaction with Hsp70 (Moroi
et al., 2000; Flechtner et al., 2006). Enhancement of
antigen-specific T cell stimulation was shown to depend
on the degree of complex formation between Hsp70 and
peptides (Bendz et al., 2007). As the physiological capa-
city of APCs to cross-present antigen is generally low
(Maecker et al., 2001), there is significant interest in re-
agents and mechanisms that enhance the targeting of
exogenous antigens to APCs. An improved understand-
ing of the interaction of Hsp70 molecules with antigenic
peptides will therefore aid the development of more
effective vaccines.
We developed an assay to analyze the interaction of
human Hsp70 with tumor-associated peptides by com-
parison with a standard peptide known to bind cytosolic
mammalian Hsc70 and human Hsp70 (Fourie et al., 1994;
Takeda and McKay, 1996; Davis et al., 1999). Since
extracellular ATP levels are generally low, our study
focuses on the nucleotide-free state of Hsp70, which is
known to have high affinity for substrate. The equilibrium
binding parameters determined show that the affinity of
the antigenic peptide molecules that bind to the chap-
erone protein can be related to the efficacy of being pre-
sented by human APCs for T cell stimulation in the
context of Hsp70 as delivery vehicle.
Results and discussion
Peptide binding by human Hsp70
Recombinantly expressed human Hsp70 was purified
and shown to possess ATPase activity (data not shown)
consistent with the literature (Wegele et al., 2003). Absor-
bance spectroscopy of the purified recombinant human
Hsp70 shows a spectrum typical of a protein sample with
no obvious contribution of nucleotides to the signal at
260 nm (data not shown). In order to analyze peptide
binding to Hsp70, we synthesized a peptide (AF-1, see
Table 1) with the amino acid sequence FYQLALT (single
letter code), which has been used previously to study
cytosolic mammalian Hsc70 binding (Takeda and McKay,
1996). Size exclusion chromatography has previously
been used to quantify binding of AF-1 peptide labeled
with fluorescein at the N-terminus (Takeda and McKay,
1996). Using size exclusion chromatography, we found
that human Hsp70 was a mixture of monomer and dimer
typical for this protein (data not shown). Fluorescein-
labeled AF-1 (FAF-1) was detected by fluorescence sig-
nal and seen to elute much later than Hsp70, at a much
higher volume than the total column volume. It has been
suggested that the elution volume of FAF-1 was greater
than the column volume in the presence of 200 mM KCl
due to salt-dependent hydrophobic interaction of the
peptide with the column matrix (Takeda and McKay,
1996). Incubation of Hsp70 with FAF-1 clearly leads to
peptide binding, as a fluorescence signal is detected at
the retention time of free Hsp70. In the presence of
excess unlabelled peptide (AF-1), a diminished fluores-
cence signal is observed at the retention time of free
Hsp70. The competition of unlabelled peptide for Hsp70
demonstrates specific binding of the peptide; however,
quantitative data were not derived from this assay. There-
fore, we developed a spectroscopic assay to compare
the Hsp70 binding affinities of synthetic peptides at
equilibrium.
Quenching of the fluorescence emission of the labeled
FAF-1 peptide is observed upon interaction with Hsp70,
with up to 20% loss in signal (data not shown). Titration
of the protein into a peptide solution results in a concen-
tration-dependent decrease in fluorescence signal which
can be quantified. Equilibrium binding parameters for
FAF-1 interaction with human Hsp70 in the nucleotide-
free state were calculated from fluorescence titrations by
fitting the data to binding equations (Table 1). While a
dissociation constant (Kd) of 5.0 ("0.9) mM was deter-
mined at 378C, binding is clearly stronger at 258C with a
Kd of 0.58 ("0.10) mM (Figure 1). The value at 258C was
confirmed by performing a titration with FAF-1 at five
times lower concentration, yielding a Kd of 0.36 ("0.08)
mM (Figure 2). A comparable increase in equilibrium con-
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Figure 1 Interaction of human Hsp70 with a cytosolic mam-
malian Hsc70 binding peptide.
Fluorescence titrations of 0.5 mM FAF-1 peptide with Hsp70 at
258C in the presence of 1 mM ADP and at 258C or 378C in the
absence of ADP. A titration with 0.085 mM FAF-1 was performed
at 258C.
Figure 2 Competition of unlabeled peptide with a cytosolic
mammalian Hsc70 binding peptide.
Fluorescence titrations of unlabeled competitor peptide (AF-1)
with 0.25 mM and 2 mM Hsp70 at 258C, or with 0.5 mM FAF-1
and 5 mM Hsp70 at 378C.
Figure 3 Interaction of human Hsp70 with antigenic peptides
from tyrosinase protein and melanoma antigen recognized by T
cells at 258C.
Fluorescence titrations of unlabeled tyrosinase and MART-1
peptides with 0.2 mM FAF-1 and 0.75 mM Hsp70, and of unla-
beled MART-L peptide with 0.25 mM FAF-1 and 2 mM Hsp70.
stant at higher temperature has been reported for a
DnaK-peptide complex (Farr et al., 1995). The large acti-
vation enthalpies observed for peptide association and
dissociation (Farr et al., 1995) are consistent with the
major conformational changes associated with substrate
exchange (Stevens et al., 2003).
ADP-bound and nucleotide-free states of Hsp70 are
known to have high affinity for substrate (Mayer and
Bukau, 2005). To quantify the effects of the nucleotide
state upon peptide binding, we performed fluorescence
titrations in the presence of ADP or ATP. The initial fluo-
rescence emission of FAF-1 peptide before titration with
protein is reduced in the presence of nucleotide (data not
shown). Binding is weaker in the presence of ADP (use
of an ATP-depleting system as described in the materials
and methods section removed any contaminating ATP)
with a Kd of 1.7 ("0.2) mM at 258C (Figure 1), and much
weaker in the presence of ATP. The rapid exponential
increase in fluorescence signal observed upon addition
of ATP to a mixture of FAF-1 and Hsp70 is attributed to
peptide release, demonstrating that the assay system
responds in a reversible manner (data not shown). Pre-
viously, the FAF-1 peptide was shown to bind mamma-
lian Hsc70 with a Kd of 4.3 mM in the presence of ADP
(Takeda and McKay, 1996). Hsp70 and Hsc70 isoforms
are conserved in the residues believed to be responsible
for peptide binding specificity and allosteric communi-
cation (Mayer et al., 2000; Ferna´ndez-Sa´iz et al., 2006),
so their binding affinities are not expected to differ
greatly. The lower Kd value determined here may reflect
the use of an equilibrium technique different to the bind-
ing assays employed in previous work.
To compare the binding affinities of different peptides,
unlabelled peptide was added to FAF-1 complexed with
Hsp70 under simple binding conditions. Competition for
Hsp70 binding leads to release of FAF-1 molecules and
a resultant fluorescence increase. Fluorescence titration
of unlabeled competitor peptide demonstrates that bind-
ing is reversible and specific. Using this novel assay, we
found that AF-1 peptide bound Hsp70 with Kd values of
2.3 ("0.1) mM at 378C and 0.87 ("0.06) mM at 258C
(Figure 2). The binding parameters obtained for AF-1
peptide from competition experiments clearly agree with
the FAF-1 binding data (Table 1).
Binding of antigenic peptides
Antigenic peptides derived from tyrosinase protein and
melanoma antigen recognized by T cells (MART-1), with
the amino acid sequences YMNGTMSQV and AAGI-
GILTV, are recognized on human leukocyte antigen
(HLA)-A2 positive melanomas by cytotoxic T lympho-
cytes (Kawakami et al., 1994; Wo¨lfel et al., 1994).
Although tumor-associated peptides were shown to be
associated with human Hsp70 (Ishii et al., 1999), their
interaction has not been reliably quantified. To compare
the affinity of the tyrosinase and MART-1 epitopes for
Hsp70, we performed competition experiments with syn-
thetic peptides. Fluorescence titration of unlabeled com-
petitor peptide with FAF-1 and human Hsp70 at 258C
yielded a Kd value of 31.6 ("4.5) mM (Figure 3), for tyros-
inase peptide. Clearly, the Hsp70 binding affinity of the
tumor-associated peptide is weaker than the standard
peptide. Antigen presentation studies show that modifi-
cation of the MART-1 epitope sequence to LAGIGILTV
(MART-L) improves binding by HLA-A2 class I histocom-
patibility molecules (Rivoltini et al., 1999). To determine
whether this amino acid substitution affects binding of
the peptide to Hsp70, we performed a fluorescence titra-
tion (Figure 3). Hsp70 binding of the modified and natural
epitopes was found to be similar with a Kd of 1.6 ("0.2)
mM determined for the modified MART-L peptide and 2.4
("0.8) mM for the natural MART-1 peptide (Figure 3).
However, the antigenic peptides derived from the
tumor-associated proteins tyrosinase and MART-1 clearly
differ in their Hsp70 binding affinities (Table 1). This dif-
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Figure 4 Interaction of human Hsp70 with a Hsp70 binding
peptide (pep70) and pep70-hybrid peptides.
Fluorescence titrations of unlabeled pep70, pep70-tyrosinase
and pep70-MART-L peptides with 0.25 mM FAF-1 and 2 mM
Hsp70 at 258C.
Figure 5 Hsp70-binding enhances cross-presentation of tyro-
sinase peptide.
B-LCL L724.45 cells were incubated with tyrosinase or pep70-
tyrosinase peptide alone (dark bars) or pre-incubated with
Hsp70 to allow complex formation (light bars). IFN-g secretion
by the antigen-specific T cell clone TyrF8 was measured by ELI-
SA. The relative IFN-g release is presented which is derived
through normalization to the IFN-g release achieved with the
peptides alone; bars represent the mean of triplicate determi-
nations"mean deviation.
ference reflects their increasing hydrophobic content to
some extent.
Binding of hybrid peptides
High transfer of antigen to APCs for MHC class I pres-
entation is desirable for vaccine development. Hybrid
peptides containing the antigenic sequence of the T cell
epitope and a BiP binding motif (here named pep70,
amino acid sequence HWDFAWPW) (Flynn et al., 1991)
have been used to enhance their interaction with Hsp70
(Moroi et al., 2000; Flechtner et al., 2006). In our assay,
tight binding was observed for the pep70 peptide alone,
with a Kd value of 0.039 ("0.006) mM at 258C (Figure 4).
Obviously, the pep70 sequence binds to Hsp70 much
more tightly than any of the investigated antigenic pep-
tide sequences (Table 1). Previously, dissociation con-
stants of 0.04 to 0.2 mM were measured between DnaK
and peptides derived from region C of the heat shock
transcription factor s32 in a competition assay (McCarty
et al., 1996).
The determined Kd values of the peptide sequences for
binding to Hsp70 can be related to their amino acid
sequence. BiP-binding peptides were shown to be rich
in hydrophobic amino acids, particularly leucine or tryp-
tophan (Knarr et al., 1999), and a motif has been pro-
posed with the sequence Hy-(W/X)-Hy-X-Hy-X-Hy, where
Hy is a large hydrophobic or aromatic amino acid and X
is any amino acid (Fourie et al., 1994). Studies with DnaK
identify a motif with a core of four or five hydrophobic
residues, where leucine is particularly enriched, with
flanking regions enriched in basic residues (Ru¨diger et al.,
1997). Although it is clear that tyrosinase peptide lacks
core hydrophobic residues, the MART-1 and pep70 pep-
tides have a similar content of hydrophobic side chains.
However, MART-1 peptide contains just one preferred
leucine and AF-1 contains two leucines, compared to
three tryptophans in the pep70 sequence. In addition, the
pep70 sequence contains large aromatic side chains at
alternate positions which may account for its 60-fold
stronger binding with Hsp70 than shown by the epitope.
Hybrid peptides combining the pep70 sequence with
the natural tyrosinase (pep70-tyrosinase) and modified
MART-1 epitopes (pep70-MART-L) were produced and
their interaction with Hsp70 was determined. Using flu-
orescence titrations (Figure 4), we determined Kd values
of 0.056 ("0.007) mM for pep70-tyrosinase and 0.093
("0.022) mM for pep70-MART-L, which are much lower
than for the individual nonameric T cell epitope sequences
(Table 1), confirming that the pep70 sequence confers a
strong interaction with Hsp70. Although the residues in
the hybrid peptide that bind Hsp70 are not known, it is
most likely that the binding observed occurs through the
pep70 motif, particularly for the pep70-tyrosinase pep-
tide, as the nonameric tyrosinase sequence is largely
devoid of Hsp70 interacting amino acids.
Antigen cross-presentation by B-lymphoblastoid
cells in the presence of Hsp70
Next, we determined the effect of peptide:Hsp70 binding
affinity on the efficacy of peptide cross-presentation in
the context of Hsp70 as delivery vehicle (Figure 5). We
used our previously established cross-presentation sys-
tem which includes B-lymphoblastoid cell lines (B-LCL)
L724.45 or L721.174 as APCs exposed to the same
amount of peptide either as peptide:Hsp70 complexes or
as peptide alone (Bendz et al., 2007). The Hsp70-medi-
ated enhancement of antigen cross-presentation was
compared between peptides, for which different binding
efficacies to Hsp70 had been demonstrated (Table 1).
The efficacy of antigen cross-presentation was deter-
mined by measuring the gamma interferon (IFN-g) secre-
tion of antigen-specific T cells. Antigen-specific T cells
secrete IFN-g after exposure to APCs and the amount of
IFN-g release correlates to the amount of presented anti-
gen. To define whether the affinity by which the peptide
binds to Hsp70 contributes to the cross-presentation effi-
cacy, IFN-g secretion obtained with peptide:Hsp70 com-
plex-loaded APC was normalized to that obtained with
peptide in the absence of Hsp70.
As seen in Figure 5 for the tyrosinase-specific T cell, a
greater than two-fold enhancement in IFN-g release was
observed for the pep70-tyrosinase hybrid peptide when
pre-incubated with Hsp70 to allow peptide:Hsp70 com-
plex formation, while Hsp70 achieved no enhancement
for the tyrosinase epitope which lacked the Hsp70 bind-
ing sequence. Similar results were obtained when com-
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Figure 6 Hsp70-binding enhances cross-presentation of
MART-L peptide.
B-LCL L724.174 cells were incubated with MART-L or pep70-
MART-L peptide alone (dark bars) or pre-incubated with Hsp70
to allow complex formation (light bars). IFN-g secretion by the
antigen-specific A42-CTL was measured by ELISA. The relative
IFN-g release is presented which is derived through normaliza-
tion to the IFN-g release achieved with the peptides alone; bars
represent the mean of triplicates"mean deviation.
paring the Hsp70-assisted cross-presentation of
pep70-MART-L with MART-L (Figure 6). Thus, Hsp70 only
enhanced cross-presentation of pep70-hybrid peptides
containing the Hsp70-binding sequence, while no effect
of Hsp70 was seen for peptide nonamers which lacked
this sequence and have very low binding to Hsp70. The
pep70 sequence itself does not interfere with the T cell
stimulation (not shown), because it neither has an appro-
priate amino acid motif to bind to the HLA-A2 molecule
nor does it have a sequence that stimulates the tyrosi-
nase or MART-1-specific T cell receptors.
The binding parameters determined for the individual
peptide sequences (Table 1) correlate with the capacity
of Hsp70 to enhance cross-presentation of exogenous
peptide (Figures 5 and 6). Although the effects of increas-
ing temperature and volume following addition of the
APCs need to be considered to fully understand the rela-
tionship between peptide binding affinity and antigen
presentation, temperature- and volume-associated
effects were minimized in our system, as peptide:Hsp70
complexes were always pre-formed in identical volume,
buffer and temperature (258C) before exposure to APC
for uptake and antigen presentation. In our previous
study, we analyzed the mechanism of Hsp70-assisted
cross-presentation in some detail. We were able to show
that Hsp70-mediated enhancement was dependent on
peptide:Hsp70 complex formation resulting in enhanced
uptake into the APC (Bendz et al., 2007).
Our results document that in an in vitro setting of vac-
cine generation, the antigen delivery to the APC can be
optimized by using designed hybrid peptides together
with Hsp70 as delivery vehicle. Multivalency of the T cell
response is the desirable outcome of vaccination set-
tings. This requires APC to present a multitude of differ-
ent epitopes. Due to different uptake properties, peptides
of a mixture are generally not presented equally resulting
in T cell bias. Endowing peptides with an identical Hsp70
binding sequence and using Hsp70 as delivery vehicle
will aid equal uptake of the peptides within a mixture
which is a desirable property for vaccine design.
In summary, we describe a useful spectroscopic assay
for measuring dissociation constants less than 100 mM
between peptide and Hsp70. Using this new assay, we
show that tumor-associated peptides differ in their
binding affinities for human Hsp70. Fusion of the anti-
genic epitope with a Hsp70-binding motif confers a
strong interaction with Hsp70 to give dissociation con-
stants of 60–90 nM. Peptides with stronger binding to
Hsp70 are better cross-presented and lead to stronger T
cell activation than peptides which lack this sequence
and have lower binding to Hsp70. Antigen cross-pres-
entation is the required pathway for the generation of
protein-based vaccines that are intended to stimulate
antigen-specific CD8 T cells. One critical parameter,
which defines the potency of T cell stimulation, is the
efficiency of delivery of exogenous antigen to the APC.
Our observation suggests that vaccine efficacy can be
improved by using antigenic sequences containing the
Hsp70 binding motif in the context of Hsp70 as an anti-
gen delivery vehicle.
Materials and methods
Purification of Hsp70
DnaK-deficient Escherichia coli strain WKG191 (Kelley and
Georgopoulos, 1997) cells transformed with plasmid pMPM-A4
(Mayer, 1995) expressing human Hsp70 were grown at 308C in
Luria-Bertani medium containing ampicillin (100 mg/ml) and
induced overnight with 0.1% (w/v) L-arabinose. Cells were dis-
rupted in 50 mM Tris-HCl, pH 7.6, containing 5 mM dithiothreitol
and protease inhibitor mix G (Serva, Heidelberg, Germany) and
the extract was centrifuged (40 000 g, 40 min at 48C). The super-
natant was separated by anion exchange chromatography at
48C on a column (2.5=10 cm) of Q Sepharose Fast Flow (GE
Healthcare Life Sciences, Munich, Germany) equilibrated in
25 mM HEPES/KOH, pH 7.6, 50 mM KCl, 5 mM MgCl2, 1 mM
ethylenediaminetetraacetic acid (EDTA), 10 mM 2-mercaptoetha-
nol. After washing the column with starting buffer, a linear gra-
dient of 50–500 mM KCl over 500 ml was applied. The
Hsp70-enriched fraction was identified by Tris/glycine sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
in the presence of the reducing agent, 2-mercaptoethanol
(Laemmli, 1970). Hsp70 was precipitated by slowly adding
100% ammonium sulfate solution at 48C with stirring to yield a
final concentration of 60% and centrifuged (40 000 g, 40 min at
48C). The pellet was resuspended in 10 mM K phosphate buffer,
pH 7, dialyzed (Spectra/Por membrane, molecular weight cut-
off 6–8000) against the same buffer, and applied to a column
(1.5=14 cm) of hydroxyapatite (Bio-Rad, Munich, Germany)
equilibrated in the same buffer at 48C. After washing the column
with starting buffer, a linear gradient of 10–400 mM K phosphate
buffer, pH 7, over 500 ml was applied. After SDS-PAGE analysis,
purified Hsp70 was dialyzed against 25 mM HEPES/KOH, pH
7.6, 150 mM KCl, 5 mM MgCl2 at 48C, then concentrated with
an Amicon stirred cell (Ultracel YM-30 ultrafiltration membrane;
Millipore, Schwalbach, Germany). Protein stocks were stored at
-808C and concentrations were estimated by absorption at
280 nm.
The identity and integrity of the purified Hsp70 was confirmed
by matrix assisted laser desorption ionization mass spectro-
metry, circular dichroism spectroscopy and Western analysis
using mouse anti-human Hsp70 monoclonal antibody (Affinity
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BioReagents, Thermo Fisher Scientific, Rockford, USA) and its
activity was demonstrated using a spectrophotometric ATPase
assay (Norby, 1988).
Peptide synthesis
Peptides were synthesized using solid-phase methods and
Fmoc chemistry. AF-1 peptide was labeled with fluorescein at
the N-terminus by stirring a solution of unprotected peptide
(0.053 mmol) in 1 ml N,N-dimethylformamide, adding 1.5
equivalents N,N-diisopropylethylamine followed by 1.5 equiva-
lents fluorescein isothiocyanate (Sigma, Munich, Germany),
incubating overnight at room temperature and then removing
solvent in a vacuum.
Peptides were purified using reversed-phase high perform-
ance liquid chromatography, and their identities were confirmed
by electrospray ionization mass spectrometry. Lyophilized pep-
tide was dissolved in 4 M guanidinium chloride, pH 7, to prevent
fibril formation and concentrated stock solutions were stored at
-208C. Sample concentrations were determined from their
absorbance at 280 nm for unlabeled peptide or at 493 nm
(´s7.5=104 M-1 cm-1; Carilli et al., 1982; Bernhardt et al., 1983)
for fluorescein-labeled AF-1 (FAF-1), or from weight when no
chromophore was present (MART peptides).
Biotin-pep70-tyrosinase and b-pep70-MART-L peptides were
supplied by Biosyntan GmbH (Berlin, Germany) or the University
of Munich Gene Center (Munich, Germany).
Size exclusion chromatography of peptide
and Hsp70
Samples of 5 mM FAF-1 alone, 10 mM Hsp70 alone, andmixtures
of 5 mM FAF-1 and 10 mM Hsp70 in the presence and absence
of 25 mM AF-1 were incubated for 90 min at 258C. High per-
formance size exclusion chromatography of the samples was
performed using a Superdex 200 HR 10/30 column, calibrated
with a total volume of 24 ml, at a flow rate of 0.75 ml min-1 in
25 mM HEPES/KOH, pH 7.6, 150 mM KCl, 5 mM MgCl2 at 258C,
with detection of protein absorbance at 280 nm and fluorescein
fluorescence (excitation, 492 nm; emission, 512 nm). The col-
umn was calibrated by running standards (dextran, bovine
serum albumin, ferritin, chymotrypsinogen) under the same
conditions.
Fluorescence titration of peptide with Hsp70
Fluorescence emission data were recorded with a FluoroMax-2
fluorescence spectrometer (excitation, 492 nm; emission,
512 nm). Samples of FAF-1 at 85–500 nM (see legend to
Figure 1) in 25 mM HEPES/KOH, pH 7.6, 150 mM KCl, 5 mM
MgCl2, were analyzed in a stirred cuvette at 258C or 378C. Initial
experiments in the presence of commercial ADP suggested the
presence of contaminating ATP; therefore, we used an ATP-
depleting system (hexokinase/glucose) for our titrations. A 1.5-
ml sample containing 0.5 mM FAF-1 peptide in the presence of
1 mM ADP, 10 mM glucose and 7.5 U hexokinase was titrated
with Hsp70. Data were collected after incubation periods of
15–210 min following addition of aliquots of Hsp70 (at concen-
trations of 125 or 350 mM), depending on the relaxation kinetics
of the system being measured, and signal over a period of
200–1000 s was averaged. Experiments were repeated and con-
trol samples of FAF-1 incubated under identical conditions did
not show loss of fluorescence signal with time. Fluorescence
signal, corrected for dilution during titration, was expressed as
a percentage fluorescence change and plotted against the total
concentration of Hsp70. Data were fitted to a quadratic binding
equation for fluorescence quenching using the Marquardt non-
linear least-squares algorithm within the GraFit 3.00 analysis
software (Erithacus Software Ltd., East Grinstead, UK):
FsF ØaqF ,a 0
where F0 is the fluorescence intensity and Fa is the amplitude of
the change in signal upon binding, and a is the fraction of FAF-
1 peptide molecules in the bound state:
2PqLqK - PqLqK -4P ØLyŽ .0 0 d 0 0 d 0 0
as ,
2P0
where P0 is the total concentration of FAF-1 peptide; L0 is the
total concentration of Hsp70; and Kd is the dissociation
constant.
Fluorescence titration of unlabeled competitor
peptide
Samples of FAF-1 at a concentration (200–500 nM, detailed in
legends of Figures 2–4) below the Kd (simple binding conditions)
were incubated with Hsp70 (750 nM–5 mM, detailed in the leg-
ends of Figures 2–4) in 25 mM HEPES/KOH, pH 7.6, 150 mM
KCl, 5 mM MgCl2, in a stirred cuvette at 258C or 378C. Fluores-
cence emission data were collected as described after incuba-
tion periods of 25–180 min following addition of aliquots of
unlabelled peptide at the following concentrations (or dilutions
thereof): 2 mM AF-1; 3.4 mM pep70; 16 mM tyrosinase; 11.6 mM
MART-L; 15.5 mM MART-1; 1.2 mM pep70-GSG; 5.4 mM pep70-
tyrosinase; 6.3 mM pep70-MART-L. Experiments were repeated.
Fluorescence signal corrected for dilution was expressed as a
percentage fluorescence change, plotted against the total con-
centration of competitor peptide (I) and fitted with fixed Kd to
the equation:
B EL0FsFqF Ø0 a B EIC F
C FLqK Ø 1q0 dD D G GKi
where Ki is the dissociation constant for the I:L complex.
In vitro cross-presentation assay
Cross-presentation was performed as described recently using
highly purified recombinant human Hsp70 (Bendz et al., 2007)
and peptides and APCs as indicated. In brief, 10 mM pep70-
tyrosinase peptide or 0.05 mM tyrosinase peptide, or 70 nM
pep70-MART-L peptide or 2 mM MART-L in 25 mM HEPES/KOH,
pH 7.6, 150 mM KCl, 5 mM MgCl2 was added to wells of a 96-
well cell culture plate and pre-incubated with 1 mM Hsp70 or a
corresponding volume of buffer at 258C. After 4 h, B-LCL
L724.45 or L721.174 cells (15 000 in 90 ml AIM-V medium) were
added, and incubated at 378C to allow uptake. After 1 h, the HLA-
A*0201-restricted tyrosinase peptide Tyr368-376 (YMNGTMSQV)-
specific cytotoxic T cell clone TyrF8 (kindly provided by Dr. P.
Schrier, Department of Clinical Oncology, Leiden University Hos-
pital, Leiden, Netherlands) (Visseren et al., 1995) or Melan-A/
MART-1 peptide27-35 (AAGIGILTV)-specific A42-CTL (kindly
provided by M.C. Panelli, National Institute of Health, Bethesda,
MD, USA) were added (4000 cells/90 ml) in RPMI medium
containing 10% fetal calf serum, 10% human serum and rIL-2
(50 U/ml; Proleukine, Cetus Corp., Emeryville, CA, USA). After
24 h at 378C, supernatants were harvested and the content of
IFN-g was measured by ELISA (OptEIA; Pharmingen, San Die-
go, USA). Control samples, containing all components except
the peptide, were used to determine IFN-g background, which
was subtracted from the experimental sample.
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